What we dont know yet Because GLP-1s havent been around for very long in the US, Ozempic was FDA-approved for use in adults with type-2 diabetes in 2017 and is not currently FDA-approved for weight loss, while Wegovy was approved for weight loss in 2021 there are no concrete answers yet about the implications of these drugs on the skin
oral daily (Rybelsus) Tirzepatide Weekly injection (Mounjaro/Zepbound) Trial weight loss Tesofensine About 10% at 0.5 mg over 24 weeks (Phase 2 and Phase 3) Semaglutide About 15% over 68 weeks (STEP trials) Tirzepatide About 21% over 72 weeks (SURMOUNT trials) FDA status (June 2026) Tesofensine Not approved for any indication Semaglutide Approved (Wegovy for obesity, Ozempic for type 2 diabetes) Tirzepatide Approved (Zepbound for obesity, Mounjaro for type 2 diabetes) Main safety concern Tesofensine Heart rate rise, insomnia, mood Semaglutide Nausea, GI upset, rare pancreatitis Tirzepatide Nausea, GI upset, rare pancreatitis Direct head-to-head trials between tesofensine and GLP-1 drugs have not been run
It is an exciting time in the field of health and wellness, with the promise of more effective strategies on the horizon
Las compresas fras para uso mdico estn permitidas, incluso si no estn completamente congeladas, aunque pueden requerir inspeccin adicional
Are highly skeptical of transdermal supplement delivery: If you have significant doubts about whether botanical compounds can be effectively absorbed through the skin, this concern is worth considering
The company was cleared to manufacture and market a once-weekly injectable treatment for adults whose type 2 diabetes is not adequately controlled
